BioMarin Eyes Late 2021 Launch As Achondroplasia Drug Succeeds In Phase III

R&D president Hank Fuchs said vosoritide can be filed based on height gains for children and safety in babies and toddlers with the most common form of dwarfism, but timing depends on meetings with regulators.